MPLT: Fails ASD Trial
MapLight Therapeutics' IRIS A Phase 2 study of ML-004 in Autism Spectrum Disorder did not meet its primary endpoint
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
MapLight Therapeutics' IRIS A Phase 2 study of ML-004 in Autism Spectrum Disorder did not meet its primary endpoint